Good day. Thank you for standing by. Welcome to the Option Care Health Q4 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one one on your telephone. You will hear an automated message advising that your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Nicole Maggio, Senior Vice President of Finance. Please go ahead. Good morning. Please note that today's discussion will include certain forward-looking statements that reflect our current assumptions and expectations, including those related to future financial performance and industry and market conditions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. We encourage you to review the information in today's press release, as well as in our Form 10-K, filed with the SEC regarding the specific risks and uncertainties. We do not undertake any duty to update any forward-looking statements except as required by law. During this call, we will use non-GAAP financial measures when talking about the company's performance and financial condition. You can find additional information on these non-GAAP measures in this morning's press release, posted on the investor relations portion of our website. With that, I will turn the call over to John Rademacher, President and Chief Executive Officer. Thanks, Nicole. Good morning, everyone. Thank you for joining us. We're excited to share updates on our productive year and the 2025 results today. Before I do this, I want to take a moment to say thank you to the entire Option Care Health team for their consistent execution and commitment to our mission of transforming healthcare by improving outcomes, lowering total cost of care, and delivering hope to our patients and their families. Before I get into the details on our business and financial performance, I'd like to reinforce our critical role across the healthcare industry. Option Care Health is uniquely positioned as the nation's largest independent provider of home and alternate site infusion therapy. We've built a strategy on a national scale that starts with putting the patient at the center, provides high-quality care with cost advantages, and fosters clinical innovation with local responsiveness. Last year, we served over 315,000 unique patients across a range of therapeutic categories, ranging from IV antibiotics to some of the most sophisticated, rare, and orphan products in the marketplace. In fact, last year, we completed over 2.5 million infusion events. Our 50-state licensure, expansive footprint, and comprehensive nursing team help us deliver consistent clinical outcomes and same-day service for large health systems and national payers across the country. This includes helping payers shift care into lower-cost settings and reduce inpatient utilization where clinically appropriate. With the ongoing economic pressures the healthcare industry is facing, we are on the right side of the healthcare cost curve, partnering to provide high-quality care at an appropriate cost in a setting in which patients want to receive it. As we reported this morning, our results were in line with what we pre-announced in January. Meenal will provide more detail. I wanted to highlight the solid execution that drove our performance this past year. In 2025, the Option Care Health team continued to capitalize on industry dynamics and made significant progress in our efforts to create a sustainable growth enterprise. We opened new infusion suites and pharmacies, deployed innovative technology, deepened our referral base, and expanded our formulary while navigating a dynamic environment and shifting economics on certain therapies. As we've reaffirmed this morning, our current views on 2026 are also in line with the guidance that we communicated in January. The team continues to execute at a high level every single day. The strength of our platform, our clinicians, our local market operations, and the consistency of clinical outcomes across our national infrastructure continue to differentiate us and provide value to our stakeholders. Our partnership with payers continues to deepen as we help them navigate affordability challenges and find opportunities to right-site care. We understand the pressure our payer partners are facing with rising healthcare costs, as well as rate pressure for those with Medicare Advantage exposure. We see strong alignment between our capabilities and the outcome the payers are trying to achieve. We expect that momentum to continue. We have active site of care programs with the largest national payers. This year we added five new programs with regional health plans and two additional with nontraditional payers. These programs are seeing traction, and we expect that number will continue to grow in 2026 and beyond. We remain committed to leveraging our platform to help manage the total cost of care while producing quality outcomes through clinical oversight and helping to ensure adherence to medication care plans. On the formulary front, we see a strong pipeline of infused and injectable drugs to treat clinically complex patients. We're encouraged by the engagement with pharma manufacturers and innovators who are seeking partners with our capabilities. Our comprehensive clinical competencies, including one of the nation's largest network of infusion nurses, as well as broad market access, national scale, and local pharmacy resources, positions us as a partner of choice to help new-to-market products reach their targeted patient cohorts. Our pharma partnerships also continue to expand, including earlier involvement through clinical trial support and enhanced service and data insight programs. We continue to invest in and strengthen our programs to create specialized service offerings, clinical effectiveness reporting, and operational discipline to scale and configure programs with efficiency capture. Today, we are privileged to operate over 20 enhanced programs in service to pharma manufacturers, and we are excited about the pipeline of new programs we expect to launch in 2026 and beyond. Our referral source relationships remain strong as we have proven to be a reliable partner across health systems and specialty prescribers. Our consistent and disciplined approach helps us capture additional demand through increased reach and frequency with these referral sources. With the specialty prescriber space, we have aligned our commercial resources to improve focus on key call points. We see attractive growth vectors in neurology, autoimmune, dermatology, oncology, and rare diseases, and we expect these therapeutic areas to play a larger role over time. The breadth of our portfolio continues to expand as additional therapies and indications are added, and we are excited about the opportunities ahead. We also continue to invest in growth across our platform throughout 2025. We added talent across commercial sales, operation, and our clinical teams. We strengthened our technology stack to drive efficiency and scale. We continued to deploy artificial intelligence and automate key patient administration functions, including invoice processing and cash posting. Today, approximately 40% of our claims are processed without human intervention. We believe these initiatives will help us to grow without significant incremental labor within these functions, while improving the quality and productivity of our team members. Our ambulatory infusion clinic investments continue to progress well, with over 25 centers offering advanced practitioner capabilities. These additional investments complement our home-based and alternate site model, expand patient choice, and can support higher acuity therapies in cost-effective settings. To provide some context, on a pro forma basis for Intramed Plus, which we acquired in 2025, our infusion clinic visits grew over 25% in the Q4 over prior year, and we've seen continued momentum in both the Intramed Plus sites in South Carolina as well as within our other infusion clinic locations. We expect to further leverage our model as we navigate regulatory compliance and identify strategic locations for new clinics. Additionally, over 34% of our nursing visits this quarter occurred in one of our infusion suites or clinics, and we expect to continue to leverage the infrastructure we've built, which contributes to the results in both clinical capacity and efficiency. With that, I will turn over to Meenal for a closer look at the financial results. Meenal? Thanks, John. Good morning, everyone. As John noted, 2025 was a strong year for the organization, and our results reflect both the resilience of the business and the strength of our team. For the full year 2025, net revenue was $5.6 billion, up 13% over prior year, driven by balanced growth across acute and chronic therapies. Our teams continued to capitalize on evolving industry dynamics to capture volumes from both health systems and specialty prescribers. Acute revenue grew in the mid-teens, while chronic therapies grew in the low double digits. As discussed in our third quarter call, we began to see Stelara biosimilar adoption, which carries a lower reference price and reimbursement. For the full year 2025, we absorbed a company revenue headwind of 160 basis points from patient transitions to Stelara biosimilars, impacting our chronic portfolio. Gross profit dollars grew 7.4%. Our SG&A percent of sales declined 50 basis points versus last year to 12.1%, as we continue to see the positive impact of our efficiency initiatives and leverage. Adjusted EBITDA of $471 million increased 6% over prior year. Our EBITDA margin was 8.3%. Adjusted diluted EPS was $1.72, growing 9% and reflecting the strength of our operating performance and the impact of repurchasing our shares over the course of the year. We generated $258 million in cash flow from operations for the full year 2025. Finished the year at a net debt to leverage ratio of 2.0x. As we shared in early January, we expected to finish below our prior guidance of $320 million. Consistent with prior years, we executed on some opportunities for strategic inventory buys where we could achieve some favorable economics, including some opportunities that arose later in the Q4. Additionally, we ramped up our working capital for certain limited distribution therapies more than we had estimated, as clinical and operational investment is essential to support long-term growth. Overall, as we grew sales 13% this year, we naturally have some higher working capital carry to support the growth of our business. We are setting our 2026 operating cash flow guidance to be greater than $340 million, reflecting a 30%+ growth in cash generation versus last year. We are already executing on initiatives to reduce our working capital with a focus on inventory, as we believe a significant portion is timing related. We are also taking a fresh look at our processes and practices around working capital management to continue driving our strong cash conversion cycle. Consistent with prior years, our cash generation is seasonal, with the Q1 historically being the low point and the majority of our cash being generated in the back half of the year. Turning to capital allocation, we executed on all fronts in 2025. Our priorities remain consistent. Our primary focus remains internal investment to support profitable growth, capacity, and efficiency initiatives. In 2025, we added over 80 infusion chairs as we continued to build out our suite and clinic footprint, where we identified strategic geographic growth opportunities, but we remain focused on maximizing utilization within our current infrastructure. We also invested in adding key clinical and commercial resources to the team. On our second priority, M&A, we remain active on identifying complementary tuck-ins and adjacencies. We acquired Intramed Plus earlier in the year, and the business and financial performance beat our initial expectations. We will continue to exercise discipline as we evaluate potential acquisitions, ensuring they are both strategic and financially attractive. Finally, we will periodically buy back our shares. We repurchased over $300 million of our shares during 2025, and as we announced in early January, the board expanded our share repurchase program authorization by $500 million. As we look forward to 2026, we are reaffirming the guidance we announced in January. We expect full year 2026 revenue of $5.8 billion-6 billion, which reflects a 4% growth at the midpoint and a 400 basis point revenue growth headwind, driven by STELARA IRA and STELARA biosimilars conversion. We are guiding to adjusted EBITDA of $480 million-505 million. This includes a $25 million-35 million gross profit headwind related to STELARA and STELARA biosimilars conversion, with the financial impact expected to be realized evenly over the year. We expect adjusted diluted EPS of $1.82-1.92. As I noted earlier, expect to generate at least $340 million in operating cash flow. On some modeling items for the full year 2026, we're forecasting net interest expense to be in the range of $50 million-55 million. We are estimating a full year tax rate in the range of 26-28%, we are assuming a share count of 159 million shares for the Q1. We are confident in the guidance we are putting forth and look forward to continuing our track record of execution. With that, I'll turn it over to the operator to open up for questions. Operator? Thank you. At this time, we will conduct the question-and-answer session. As a reminder, to ask a question, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. Our first question comes from David MacDonald of Truist. Your line is now open. Good morning, everyone. Just a couple of quick questions. John, can you talk in a little bit more detail? I mean, you know, it's hard to kind of get through a day without hearing about affordability. You talked a little bit in your prepared remarks about, you know, the payers, but can you also talk about not only just, you know, what you're seeing in terms of the payers? It sounds like those conversations are certainly, you know, incrementally ramping up. Let me know if that's accurate. Secondly, just what you're seeing in terms of conversations with potential hospital systems, just given some of the pressures that they're seeing and, you know, chatter around things potentially down the road in terms of, you know, maybe like site neutrality. You know, just any additional color there would be helpful. Yeah, absolutely. Good morning, Dave. On the affordability, as I said in the prepared remarks, you know, we're working closely with the payer community around helping to enable their focus around total cost of care and reducing that as it moves forward. We have in place, as we called out, site of care initiatives that help to identify opportunities to transition patients onto service with us and help to reduce that total cost of care, whether it's in the home, whether it's in one of our infusion suites or in one of our infusion clinics. You know, we've had programs in place. I would say the pace of those conversations has increased, as the payers have been focusing around really their MLRs and looking for opportunities to, you know, maintain quality, but do it at a lower cost. You know, we're encouraged by those conversations and the opportunities that we believe that brings to us, as well as to the patients that we have the privilege to serve. On the hospital system front, yeah, I'd say similar. You know, there have certainly been strong relationships across the country with key hospital systems, you know, focusing on helping to transition patients safely and effectively onto care with us, especially when they have a capitated DRG type of payment plan. You know, they are always looking for the ways to help to transition those patients safely out of their facilities. You know, we embed our RNs into those hospital systems to help with that transition of care. You know, we believe that that's gonna continue to be a strong point, given the national scale we have, but that local responsiveness that we talk about. That is the balance of the portfolio. You know, we talk a lot about the acute and chronic portfolio that we have. That ability to serve the breadth of products as well as the breadth of patient population, just positions us well to support the hospitals and health systems. You know, whether it's a acute discharge for a patient on an IV antibiotic, whether it's supporting a 340B program on some of the specialty drugs, we have a wide range of programs that we work with the hospitals and health systems to enable them to be able to achieve the best outcomes. Okay. Just, John, a couple of other quick ones. Just in terms of advanced practitioner, I just wanna make sure I caught that right. Could you just run through, were those pro forma numbers across the entire advanced practitioner, 25 locations? Was that just Intramed? Just, I just wanna make sure that had that correctly, down correct. Yeah. One other quick question. You talked about driving increased utilization of your existing footprint. Can you give us a sense, is it fair to assume that as some of these have matured, that roughly 20% increase that you've seen in, nursing efficiency, you know, goes higher as these things mature and you further drive utilization within those centers? Yeah. Starting with the prepared remarks, the 25% increase was the Intramed sites. you know. Okay as we took that over on a year-over-year basis, just in the comparable, continue to make investments into that marketplace as we went through the integration of that asset as being part of the Option Care Health family. Really pleased about that. You know, the rest of the sites are seeing the momentum. We didn't necessarily scale or call out the exact growth on that, Dave, just wanted to put it into perspective on the Intramed sites. On the overall, you know, efficiencies that we expect, we continue to see growth in our patient census. I mean, as I called out in the prepared remarks, we served over 315,000 unique patients last year. That is a all-time high for this organization, and it just shows the strength of the platform and our ability to reach into that. Continue to utilize the footprint, especially in the infusion suites and the infusion clinic, just allows us to drive both capacity and efficiency of the nursing network and continue to drive that forward. We had called out before the, about a 20% improvement that we see in the nursing efficiencies over time, and that's part of that equation of where we're seeing the use of those sites to really help us, you know, drive the operating efficiency and leverage, but also to increase the capacity of our nursing community. Okay. Thank you very much. Thanks, Dave. Thank you. Our next question comes from Matt Larew of William Blair. Your line is open. Hi, this is Jacob on for Matt. Thanks for taking the questions. I just wanna touch on the outlook to start. I appreciate you first guided about a month ago, and today reiterated that guide. Just wondering if you've seen anything that has made you maybe more cautious on the outlook for the year, whether that be updated numbers, expectations for Stelara. I know you reiterated the guide you had previously given for that, but just what kind of maybe early trends in the Q1 have showed you, maybe any ramping drugs or drug classes or anything from the recent IRA announcements, as well as any upcoming biosimilar launches you'd highlight that could potentially affect numbers to the, you know, the both ends of the guidance range this year? Sure. Jacob, hi. I'll answer your question, I'll give you the short answer, which is no. You know, we didn't change anything related to our guidance that we provided in January. We, of course, are keeping track of the landscape and the number of puts and takes that are going on. A lot of noise in the news these days. From where we sit and the plan that we've put together, we still feel very good about the guidance that we've set forward both from a sales growth perspective as well as profitability. You know, we also added in the cash flow guide in that. You know, we feel we haven't really seen anything that would lead us to changing anything in the guide right now. I don't know, John, if you wanna speak to trends? Yeah. I think the overall trend is in alignment with our expectations. You know, we had done a lot of planning heading into the year, and certainly when we were, you know, formulating what was going to be that pre-release guide that we put forward. I think what we're seeing at this point in time is that things are trending in alignment with kind of our expectations. As you know, the Q1 is a very busy time with benefit verification and reauthorization and prior authorization for new patients coming onto service. There's always a bolus of activity that kind of comes at the beginning of the year. It really takes the quarter to fully shake a lot of that out. At this point in time, we're very confident in the 2026 guide and continue to believe that everything is patterning in alignment with our expectations. To your broader question, and as Meenal said, there is a lot of noise in the marketplace at this point in time. We're trying to separate the signal from the noise. Again, we don't see anything in 2026 that really is changing our perspective around where we see the growth and where we see the opportunities that lie ahead. I think the team is staying close to any of those developments, but at this point in time, feel very good with the guidance that we have reaffirmed this morning. Got it. Thanks for that. I wanted to go back just quickly on the advanced practitioner model. I think in last quarter, you mentioned 24 of your 175 total facilities were equipped with this model. I think I heard over 25 this quarter. So I was just wondering what your target pace for converting and opening new sites in 2026 and beyond is? Maybe as a follow-up to that, as you scale, you know, both the infusion and, you know, these advanced practitioner models, what are kind of the key limiting factors for increasing the pace of the new site openings? Maybe what does the plan to invest in those capabilities look like in the next couple of years versus what that looked like in the last couple? You know, as we've expressed before, I mean, we have a pretty big install base of our infusion suites, and there's kind of a collective approach that we're taking on our infusion clinic build-out. Some of them are new sites that are greenfield, that we are building when we find strategic geographies in which we want to have that capability. Others are the conversion of our existing sites to transition them over and get the licensure, and there's a modest amount of refurb that needs to happen in order to make them an infusion clinic. We're kind of going about it in both ways as we see the market opportunities and driving that forward. As we called out, as you heard, we have continued to grow that in the Q4, and we expect that we're going to continue that conversion and growth into 2026. You know, I don't know that I'm willing to put a target out there at this point in time. It moves it in some way, an interesting pace. I think as we've explained before, a lot of it has to do with corporate practice of medicine at a state level and the ability to get credentialing with the payers through that process. You know, we're actively moving forward with that. One of the big, you know, aspects of where we really can drive the utilization is the investments that we also called out in investing in our commercial resources. Having the sales team that is making the call, certainly, investing in the clinical resources that are necessary to be able to oversee those clinics and operate within that environment. This balance of the operating model, but where a patient is best served under the practice of pharmacy or where a patient is better served under the advanced practitioner model and balancing those out. We continue to make investments across all those dimensions. We believe this is additive to our overarching strategy of being a partner of choice and having, you know, a choice for patients to select the best site for their care. We're going to continue down the pace, and I would expect that you're going to continue to hear us talk about the growth that we're seeing in the existing install base, as well as continue to make additional investments to expand our capabilities and expand the network of advanced practitioner clinics. Thank you. Our next question comes from Pito Chickering of Deutsche Bank. Your line is now open. Good morning, guys. Thanks for taking my questions. I guess the first one here, just a quick housekeeping. Can you quantify the Stelara impact that you guys saw in the Q4 as want to be able to model what gross profit growth year-over-year was excluding the Stelara? You know, was that in line just for $20 million-22 million of EBITDA impact in the Q4? Yeah, the short answer is yes. You know, in the end, for Stelara and the headwind that we talked about, you know, which was close to $70 million or so, it patterned out exactly as we thought. If you assume about $20 million of an impact in the Q4, maybe a little more, that's over a 100 basis point impact to gross profit. Okay, perfect. You know, looking at your split between acute and chronic growth for 2026, just sort of curious how you view the acute growth this year. Obviously, it's been a couple of big years post, you know, like your competitors exiting. How do you view the revenue growth of acute in 2026? Also the same question, how do you view the chronic growth at 2026? The follow-up there, from a margin perspective, is there any reason why the margins in 2026, you know, excluding Stelara, would change versus the last couple of years within those two segments? Thanks. You know, we expect to continue to see, you know, strength in our acute offering. You know, as you called out, Pito, you know, the marketplace continues to be dynamic there, but we believe we're well positioned. The infrastructure that we have and the capability set really plays well to capture that market demand. I think we have characterized that the industry of those types of product is a low single digit. Our expectations is probably a mid-single digit on that, so that we will continue to capture, you know, the market demand as it moves forward. That's a step down from the prior year where we had the competitive closures, but it still is a strong result on that. I would say the profit contributions on the acute would be consistent with what we would expect and what we've seen in prior years. No major changes from that perspective. On the chronic, again, given that some of the headwinds of the biosim and the Stelara, you know, we still expect that to be in the high single digit, low double-digit growth on the chronic standpoint. Again, as you had called out, certainly we have the headwind of the biosimilar and Stelara impact on a year-over-year basis. The rest of the portfolio, I would say, is in alignment with kind of what the historical expectations or the historical performance has been from that. You know, we're gonna continue to have to fight through a little bit of a mix, you know, challenge in the sense we're gonna be growing our chronic faster than the acute, and that's gonna put some pressure on the gross margin as a percentage aspect. Again, we feel good about the strength and the breadth of the portfolio. You know, as we called out, we're, you know, punching above our weight class in some of that aspect, where you're working through the headwinds of Stelara and putting that behind us in 2026. Great. Thanks so much. Thank you. Our next question comes from Brian Tanquilut of Jefferies. Your line is now open. Hey, good morning. John, maybe to follow up on your points to Pito, as I listened to your prepared remarks and heard all the things you were talking about in terms of the drivers of the business going forward, your AI benefits, and the fact that your business probably can't be AI, you know. When we think through all that, and the fact that Stelara is behind us now, is it right to think that we should revert back to sort of a double-digit EBITDA trajectory once we get to 2027? Yeah. I mean, look, Brian, we don't give 2027 guidance on the day that we gave out 2026, as you expect. The fundamentals of the business. I guess, part of the prepared remarks were around the fundamentals of business being strong. We believe we're on the right side of the cost quality equation. We believe that we continue to partner with payers and pharma, and really have a unique platform for our stakeholders to help achieve their goals as we're achieving our goals. There is, you know, there will continue to be opportunities as we see the portfolio of products that are entering the marketplace, as well as the ability to use our clinical resources to the fullest across that. I think things are setting up really well for us to continue to drive the business forward. I think we're extremely well positioned to capture that market demand and deepen the partnerships with those key stakeholders. You know, I think as we move through the year and continue to make progress against the objectives that we've outlined, I am confident in the strength of the position that we hold, and I'm really confident in the opportunities that we have to continue to capture market demand and really drive around those new vectors of growth that I outlined. Yeah, and. Yeah, go ahead. Hey, Brian. Yeah, it's Meenal. Just the other thing I'll add when we put forward our 2026 guide, you know, we talked about there's a couple of headwinds in there, 400 basis points related to hopefully the last, the last couple of quarters, we'll talk about Stelara. 400 basis points headwind on the revenue side. With the, you know, the $25 million-35 million EBITDA impact we talked about, if you take that out of the growth rate that the guidance implies, that puts us at a double-digit EBITDA. You know, that's what we're striving for, you know, echoing everything John said about a lot of the initiatives, a lot of the work that we're doing. you know, we're just really focused on 2026 as a year of execution on a number of different initiatives and investments that we've made. That's very helpful, Meenal. Maybe my follow-up, as I think about your guidance for the year, what assumptions have you made in terms of biosimilar shifting within the Stelara portfolio or even to other therapies like from Pfizer? Should ask differently, maybe, is there upside opportunity as those things occur over the course of the year? Yeah, I mean, we entered the year with, you know, assumptions around the portfolio and the census of chronic inflammatory disease, kind of the broader category, Brian, inclusive of that Stelara, knowing that there were going to be shifts to biosimilars, there were going to be shifts to other products in the portfolio, and some of it was gonna be led by the PBMs and payers around their formulary management and the way that they were aligning around those opportunities. I think, as I said, in a previous question that was asked, I think it's patterning the way we expected it to, or, you know, at least, you know, close to that, which gave us confidence to reaffirm the guidance today. You know, it's, those shifts, you know, the, the Q1 is a really important quarter just because of all the prior authorization and reset that happens through that process. I think as we get through the end of Q1, we'll have a better sense around how everything's going to shake out on that. At this point in time, it's in alignment with kind of our expectations. There's really nothing else that is on the horizon in 2026 that we think has, you know, material impact on the portfolio, either with new product entrants or biosimilar conversions other than the Stelara, as we have called out. Awesome. Thank you, guys. Yep. Thanks, Brian. Thank you. Our next question comes from Lisa Gill of JP Morgan. Your line is now open. Thanks very much, good morning. John, I wanted to go back to your comments around the expanded formulary. You talked about a strong pipeline in infused and injectable products. Can you maybe just talk about any specific opportunities that you see? I know in the past you've called out, for example, rare and orphan products and, you know, large dollar amounts, but smaller gross margin%. Anything that we should keep our eye on as we think about 26? Then just kind of dovetailing into that, when I think about the strategic inventory buys, you know, that you talked about, should we think about that also as, you know, more of a Q1 impact, or is that also going to be spread throughout the year? How do I think about the cadence of some of this? Yeah. I'll start, Lisa. Yeah, thanks for the question. I think, you know, when you look at the formulary and the, and kind of the opportunities that we see in the pipeline, I would guide us a little bit more towards some of the rare, you know, products. The platform that we have, the clinical capabilities, you know, we have, and we had announced earlier that we have two additional platforms that are going to be starting in 2026. A little bit hard on some of those products to know, what the uptake is going to be and, you know, with producer dates and, and things of that nature as to when the actual launch will happen. We have two programs that will come online in 2026, in addition to the portfolio that we have. You know, we think the platform itself has strength in the pharmacy infrastructure, the infusion suite infrastructure, and the clinic infrastructure, as well as the clinical competencies that we have to continue to partner deeply with pharma on that. I think you'll hear more about that as things progress, and those are areas of focus. You know, there are additional, you know, products that are coming in in the chronic space, that again, we feel encouraged about, either expanded indications and/or an opportunity for entrants of new products into the portfolio. Look, I'm not going to call out single products, you know, for various reasons, but the strength of the team that we have in place that works with pharma manufacturers to identify those opportunities, to make certain that we're on formulary or it's a part of our formulary, and we're able to bring it in, and in some instances, either through a limited distribution or exclusive arrangement, we're always looking for how to leverage our infrastructure to the fullest and be a really strong partner to pharma as they're looking for channel partners to be able to reach their patient cohorts. Yeah, Lisa, I'll answer the cash flow question for you. You know, in general, we would expect, and maybe I'll take a step back. I talked about in the prepared remarks that, you know, we had, as we've typically done, we made some strategic inventory purchases. Some there were some decisions late in the Q4 when we did that. You know, as typical during the year, we'd expect it to get used up, whether that's exactly evenly through the quarters, it's a little chunkier with cash flow, but I would expect it would go through the year. Just a reminder, I would also say that as we think about cash flow seasonality, we've historically seen where Q1 tends to be the lightest cash flow quarter, tends to be much stronger in the back half. It's hard to see where the inventory patterns will match in there, but, you know, we will comment on it, and you'll see tracking coming through with just inventory balances shrinking throughout the year. Just to follow on to your capital allocation strategy. You know, I heard both you and John talk about Intramed being very successful. How should I think about, you know, Uncertain incremental opportunities for another Intramed or, you know, other types of tuck-in acquisitions in 2026 versus share repurchase? Yeah, I mean, I'll start with this. You know, as I think about our M&A strategy, you know, we're absolutely that's a big focus. We've talked about organic investment followed by M&A. We have added additional resources, really focus on this area. We're continuing to evaluate a number of different opportunities that are out there. I just remind folks, right, you see what's above the waterline. You don't see all the swimming going on underneath the waterline. There's definitely a lot of activity and M&A remains something that we'd go after. You know, Intramed-like assets have been terrific for us as we've gone through in the past. That's definitely a focus area for us. You know, John? Yeah, and I would just echo that. You know, I think that we're managing a pipeline of opportunities at this point in time. As Neel said, you know, we continue to invest in that team, and the capabilities to assess and then do that. The only thing I will continue to remind everyone is, it's got to be both strategic and financially, you know, creative for us as we're looking forward. That's the, you know, the discipline that we've demonstrated historically, and it's one that we'll continue to maintain as we look ahead. Great. Thank you. Thank you. Yeah, thanks, Lisa. Our next question comes from A.J. Rice of UBS. Your line is now open. Thanks. Hi, everybody. Just to put a finer point on the seasonality, I'm interested on the income statement. You got the $25 million35 million gross profit headwind. I think the assumption with the way things played out last year was because you had forward buying that mitigated the impact of Stelara in the Q1 last year. The comp will be particularly tough in the Q1 this year, and then get more normalized for the rest of the year. It sounds like you've got forward buying you're doing again this year. Should we think of that $25 million-$35 million headwind as being evenly distributed, or is Q1 still gonna be a tougher comp than the rest of the year with respect to that? Yeah, let me answer both questions, A.J. One is, it relates to 2026, and I talked about, and this hasn't changed, that the $25 million-35 million headwind, we would expect to pattern out fairly evenly throughout the year. There isn't, you know, that Q1 phenomenon that occurred last year. Having said that, when you look at the year-over-year comp, because of what happened in 2025, there is a bit of a year-over-year comp issue in Q1, where it was more favorable in Q1 last year, but not necessarily this year. Hopefully that answers what you were trying to get at. Okay. No, I got it. I know John mentioned the application of AI in claims processing and things you're doing there. We're hearing providers talk about AI applications in various ways. I was curious, when you go beyond that, is there any other applications that you're looking at for AI, whether clinician, utilization, staffing, other things that would be worth highlighting? A.J. I would highlight that we're doing work with some agentic aspects for, as you would expect, call center capabilities and the ability to help better support customer service. We're doing work around workforce optimization and making certain that we have the right resources in the right places. You know, as part of the overarching comments that Meenal made around, you know, strengthening some of the things on working capital, we're looking at tools to help better manage inventory and things of that nature. I'd say it's broader than just revenue cycle management at this point in time. The use cases that we have are expanding. You know, these are all, I guess, tools that augment our team. They help our team work more efficiently, more effectively, and in instances, you know, reinforce quality through that process. We have not done anything at this point in time to really put it in front of the clinician. You know, we believe that the models are still a little bit immature in order to do that. We may look for opportunities to help support our clinicians in note capture and other aspects, but at this point in time, we have not done anything to put it in the pathway of the clinical protocol. Yeah, the other thing, that, A.J., is just, you know, as, you know, as AI becomes, dare I say, more mainstream, et cetera, you know, there's a lot more, as John referred to, certain things that are now off the shelf that we're looking at, or even when we're working with other vendors and partners, where they're utilizing, you know, AI and other tools to help us, help what they're doing for us on efficiencies. Those are other areas that are going on as well. It's much broader, as John said, it's much broader than just looking at the revenue cycle management area. Right. Okay. Thanks so much. Yep. Thanks, A.J. Thank you. Thank you. Our next question comes from Joanna Gajuk of Bank of America. Your line is open. Oh, yes. Hi, good morning. Just a couple of follow-ups. In the prepared remarks, when you talk about payers, you had mentioned five new programs with regional and two with nontraditional payers. Can you give us a little more color, especially the nontraditional payers, what exactly, are you referring to? Yeah, Joanna, it's John. You know, so there are conveners in the marketplace that are either, you know, trying to create a better solution for payers themselves and or direct to employers. Those are the nontraditional partners that we're working with that allow us to expand, you know, our reach into the marketplace, but also, you know, be a partner across the payer community at the national, regional, and the convener level. When you work with these, I guess, conveners, and I guess sounds like direct to employer relationships, I guess, are these rates comparable to what you know, negotiate with commercial payers? Maybe they're better, because it sounds like these parties look for solutions, and maybe they're willing to pay a little bit better rates. I don't know. Can you give us a little bit of flavor on that? Yeah, I would say they're comparable within the way that the reimbursement. Although, you know, some of the conveners and some of the, I guess, the more innovative organizations are continuing to take a look at capitated programs and looking for ways to help to manage the patient base in a more comprehensive way. You know, they're trying to innovate around those aspects, and, you know, we're working with them around thinking about new models as well as existing models that they're operating with, so. I would say, you know, we're seeing that they're comparable in the, in the reimbursement, and in some ways, they just help us continue to innovate and make certain that we're thinking about the total cost of care in a broader sense. Okay, that makes sense. If I may, another follow-up. You were talking, in, on multiple occasions, I guess, around cash flows, but also in terms of the product and portfolio around limited distribution drugs. Can you give us a sense of, I guess, how many you have and how many, I guess, you added in 25, how many you're adding in 26? I guess, are you seeing any increased competition for these limited distribution drugs in the marketplace right now, or less competition for that matter, but just any additional, I guess, commentary will be helpful. Thank you. Yeah, Joanna, so we have over 20 platforms that we operate today that are either rare or limited distribution drugs that are part of our portfolio. We had called out in previous calls that we were adding two additional programs in 2026 as of this point. You know, these are normally, especially on the rare side, they tend to be higher priced products. There is some working capital build that comes with that as we're putting inventory into our infrastructure and helping, you know, support the commercialization of those products. you know, that's part of the working capital, you know, that Meenal had called out and, you know, some of the things that we use cash in 25 and we'll, you know, 26 as we move forward. you know, we feel really good about the platform. When you think about the breadth on a national scale, the access points that we have, the relationships we have with the payers, and then the clinical competencies of this enterprise, you know, we continue to believe we are well positioned to compete for those. There are competitors in the space. It's, as you would expect in all of healthcare, it's, highly competitive. We believe that we're creating a very unique platform and have an opportunity to win our fair share of those type of programs as we move forward. Great. Thank you so much for the color. Thanks. You're welcome. Thanks, Joanna. Our next question comes from Charles Rhyee of TD Cowen. Your line is now open. Yeah, thanks for taking the questions. Maybe John and Meenal, you know, a month back when you guys sort of outlined sort of the initial guidance for the year, you know, I think there was sort of an assumption, you know, that you'd be looking at sort of... It was early, you didn't know what your Stelara sense would look like, and so some of the assumptions you're putting out there, you know, I think you were trying to figure out, if I understood it correctly, was, you know, taking kind of a conservative assumption on that. You know, we fast-forward here about a month and a half, you kind of reaffirm the guide. Anything about that in terms of what you have then maybe thought of what your census looked like versus what you're actually seeing now? Has anything changed or gotten better or worse? John, I think you mentioned 340B in one of the, in response to one of the questions earlier. Can you kind of talk about how you support 340B and what is your maybe any kind of exposure you have to the program? You know, I know there's some, you know, concerns around, obviously, there's some regulatory risks that pop up now and then around that. Just curious how do you work within the 340B program with your acute care partners? Thanks. Yeah, Charles, why don't I'll take the first part of your question on Stelara. You know, as we talked a little bit earlier, there's a lot of activity that always goes on in the Q1, you know, with new year benefit verification and formulary changes, and just with a lot of the broader noise across the industry right now, you know, it's been probably a lot more than that. Despite all that, when we look through all the activities and where we are today, we're not really seeing any substantial differences versus what we had assumed a month ago when we thought about, you know, I'd call it Stelara and all the different potential formulary options that could be out there for patients. You know, if there was anything that would have caused us to rethink our guide, we would have incorporated here. As I think John mentioned earlier, there really isn't anything that's substantially different, and it's still gonna take us another month or so through the end of the quarter, really, to get through all of this, the new year activity. As is pretty typical, but a little more enhanced this year, just with other industry noise going on. Charles, on the 340B side, again, this is an additive program that we operate in support of our health system and hospital partners. You know, our model is one in which, you know, we either qualify as a pharmacy under the 340B, you know, criteria, and we just pass the savings on to the hospital. We're, we certainly, you know, dispense the product and are able to, you know, to get the economics that are normal with that. Any of the 340B savings is just a transfer of those savings back to the hospital. You know, we help to facilitate that and drive that forward. I wouldn't say it's a meaningful part of our overall, you know, economics and our overall program. We, we like to support the hospital and health systems. We like to, you know, be able to bring them the benefits and the savings that could be generated when they're a disproportionate hospital. We, we work with, you know, the clearing houses and across that in order to facilitate the savings to be passed on to the hospital. Just to be clear, though, that means if there were to be any changes in 340B pricing, that would have no impact for you guys because that's sort of a pass-through on your end? correct. Yeah, I mean, that's the way. Okay. we've approached it. All right. That's really helpful. Maybe just one quick follow-up on OpEx growth for this year, how should we think about it? I think last year we saw some elevated expense related to the instrument acquisition and investments in the business. Can you give a sense, Meenal, sort of what we should be thinking about in terms of OpEx growth, anything kind of one-time or, you know, any things that are coming out? Thanks. Yeah. You know, when I take a step back, maybe I'll answer it in a 2025 context and looking forward. When I think about 2025, you know, our SG&A, you know, on print does look like it's up a little bit versus gross profit, and that's the lever that we're taking a look at. when you start to strip out, as you point out, Intramed, and there's some GAAP-only charges that are sitting in SG&A, and you take some of that out, we're actually in line or a little bit down on SG&A growth versus gross profit growth. That's, I mean, that's where we expect to trend as we think about going forward. We still have, I think, 26, maybe a little bit more on the investment side that we're doing. You may see a pattern slightly higher than gross profit, but, you know, as we look forward, we look for something closer to a leveraged model versus gross profit. Great. Really appreciate the comments. Thank you. Thank you. Thank you. Our next question comes from Erin Wright of Morgan Stanley. Your line is open. Great. Thanks. I just have kind of one bigger picture, just higher level question, just on the competitive landscape and just thinking about some of the historical tailwinds with competitors exiting the market. I guess, can you talk a little bit about the runway left on that front? How much does, you know, that continue in terms of a tailwind for you? Are there other dynamics, I guess, to call out in terms of looking at the landscape and your ability to take advantage of some of those opportunities? Thanks. Yeah, Erin, I think as we're looking ahead, we certainly don't see as big of a significant shift that we've seen over the last couple of years with two major competitors kind of resetting their network design and the product portfolio that they were serving. We still believe there's opportunities to take share in the market. You know, we're well positioned. We like the infrastructure that we've built, we love the breadth of the network, but also understand healthcare is very local, and we have to win at the local level. We're doing everything we can to be that reliable and consistent partner, to be able to help with the transition of care for patients or be able to help them live their best life, through the activities of our clinical teams in support of those care plans. You know, the market in general, I mean, if you take a look at some of the data, you know, the market for infused products is over $100 billion. You know, we're $6 billion of that. We think there's still continue runway for us to be that partner of choice and to compete vigorously, but know that this is a hustle business, and you got to do it every single day. Okay. Thank you. Thank you. Our last question comes from Raj Kumar of Stephens. Your line is now open. Good morning. Thank you for squeezing me in. Maybe just kind of thinking about the kind of investment thesis, around kind of just the internal spend, and kind of the opportunities that they've talked about around oncology and neuro. As we think about the kind of investment spend in 2026, and the, you know, capturing of said opportunity, is that more so that, you know, there's needs to be internal capability that still need to be built out or potentially acquired to, you know, capture, you know, oncology in the home-based care setting? Or is it kind of more on the, you know, sites of care initiatives front, in terms of just, you know, payer or, you know, hospital partner, acute partner education? Maybe kind of on the AI initiative front, and thinking about, you know, what was realized on 2025, any way to frame the benefit in terms of if it, you know, drove increased throughput or, you know, any cost efficiencies, that would be kind of helpful. Yeah. Let me start with maybe the AI first. You know, as we had called out, I think the measurable response is when you're able to do 40% of your claim processing without actually having human intervention, you can see the benefits that are driven on that. Again, that allows our team to focus on the higher complexity claims, those that, you know, need additional, you know, support in order for us to get, you know, fair reimbursement for the services that we rendered. You know, our focus has been around there, but we're seeing those tangible results. You know, I think you see it in both cost of service as well as SG&A over time, knowing that you've got to invest a little bit ahead of benefit on some of those to be able to drive that forward. On the overall, you know, I think we remain a capital-light enterprise. I mean, I think for the next year, you know, we'll be in that $40 million-50 million range of CapEx as we're looking at the range of opportunities to deploy capital to grow our business. We'll go about your call-out on oncology or others. You know, that's a two-pronged approach. There is investments that are required in the commercial team and being able to reach into the call points. There are some capabilities around the clinical protocols and the clinical programs that need to be developed in support of that. There's certainly the utilization of our infusion suites and our infusion clinics as part of that comprehensive view, as well as the ability to transition patients to the home. I'd say it's across all of those dimensions. You know, as we're looking at where we deploy our capital and the return we expect on those, you know, we have a disciplined approach that Meenal and team lead to help to us to really assess the value that can be created there. We think there's, you know, a significant amount of opportunities for us to look at those new vectors and continue to invest in the people, process, technology, and facilities that would be required for us to win. The last comment I'll add on that is, with all the investments John is talking about, we definitely have made investments in 2025, and you can see that. You're gonna see an annualization of that into 2026. Plus, you know, like on the commercial resources side, that's an area that we're really leaning into, and there's some additional investments we're making. That's part of the comments that I was addressing previously on still a little bit more SG&A growth that's going in ahead of the growth and the benefits we expect to achieve. Got it. Thanks for the color. Thank you. Thank you. I am showing no further questions at this time. I would now like to turn it back to the President and CEO, John Rademacher, for closing remarks. Thank you. Yeah, thanks, Amber. In closing, I want to highlight the resilience of our platform and strength of our team and the underlying fundamentals of the business. We're well positioned to take advantage of the opportunities ahead of us, and I've never been more confident in the team's ability to capture demand for the extraordinary care and hope we deliver to patients and their loved ones. Thank you, and take care. This concludes today's participation in the conference today. You may now disconnect.